Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Avacta appoints new head of research and development
(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday. The AIM-traded firm said in the role, Dr Coughlin would oversee all clinical development and pre-clinical research activities within the division.
It said Dr Coughlin, who had served as a non-executive director of Avacta Group since March 2022, had played a crucial role in driving the clinical development strategy for AVA6000, its flagship 'preCISION' tumour-targeted therapy, and the broader drug pipeline strategy.
Her background as an oncologist and immunologist would bring valuable expertise to the company, the board said.
With extensive experience in the pharmaceutical and biotech sectors, D. Coughlin previously held leadership roles at companies including Wyeth, Pfizer, Novartis, Immunocore, Tmunity, Rubius, and most recently, Cytolmmune Therapeutics.
She holds an MD and PhD from the University of Pennsylvania, and received training in haematology and oncology at the Children's Hospital of Philadelphia.
Dr Coughlin would assume her position as head of research and development on 1 February, taking responsibility for all pre-clinical research, clinical development activities, and pipeline strategy within the therapeutics division.
She would also continue to serve on the board, as an executive director.
At the same time, Avacta announced the departure of Dr Fiona McLaughlin from her role as chief scientific officer of the therapeutics division.
Dr McLaughlin had been in the position for three years, and made significant contributions to the division's development and its various programmes.
She would still work with the company during a transitional period as she steps down from her role, the board confirmed.
"Chris brings deep oncology research and development expertise combined with trans-Atlantic C-level experience from which the entire business will benefit as we evolve from a research organisation to one led by a strong clinical focus," said chief executive officer Alastair Smith.
"The outstanding safety data from the AVA6000 clinical study that we recently presented validates the preCISION platform's ability to deliver cancer drugs specifically to the tumour microenvironment."
Dr Smith said that would open up "tremendous opportunities" to develop innovative cancer medicines to improve outcomes for patients and grow shareholder value.
"The board and I would like to thank Fiona for her outstanding contribution over the past few years.
"She has added significant value to the therapeutic programmes and played a key role in building the therapeutic division's operations."
At 1100 GMT, shares in Avacta Group were up 0.48% at 103.99p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.